Results 301 to 310 of about 1,561,364 (334)

Persistence of IL-17 and TNF inhibitors following initial TNF inhibitor use in axial spondyloarthritis: a nationwide retrospective cohort study. [PDF]

Ther Adv Musculoskelet Dis
Jung YS, Cho SK, Choi SR, Jung SY, Sung YK.   +4 more
europepmc   +1 more source

Cardiac arrest triggers IL-17-mediated neuroinflammation and astrocyte polarization: insights into pathogenesis and intervention. [PDF]

J Neuroinflammation
Li S, Wang L, Luo Q, Fan M, Xu Y, Liu X, Zhang Y, Zou L.   +7 more
europepmc   +1 more source

IL-17 + γδT cell: a new target in hyperbaric oxygen treatment reducing spinal cord injury. [PDF]

J Transl Med
Liu M, Sun Z, Liang F, Yao R, Yang L, Nan D, Yang J, Su Q, Liu X.   +8 more
europepmc   +1 more source

Table 1_Efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors for psoriatic arthritis: a network meta-analysis of randomized controlled trials.docx

Shan Gao (46743), Xingxing Xie (6293498), Ling Fan (2215240), Linyuan Yu (8929973)   +3 more
openalex   +1 more source

IFN-γ and IL-17 elicit synergistic anti-mycobacterial responses by inhibiting coronin-1A retention. [PDF]

Commun Biol
Park HS, Pham TA, Jiang Z, Choi S, Back YW, Jang IT, Shin KW, Son YJ, Choi HG, Kim HJ.   +9 more
europepmc   +1 more source

Additional file 2 of Neutrophil-macrophage crosstalk via NETs–IL-17/VEGF/S100A9 axis promotes hepatocellular carcinoma progression

Rong Wu, Rui Wu, Xuehua Kong, Xuanyi Wang, Yaqian Duan, Shiyu Cao, Yu Sun, Y H Zhao, Shue Li, Zhou, Jingying, Liang Duan   +10 more
openalex   +1 more source

Diabetes exacerbates destructive inflammation by activating the CD137L-CD137 axis in dendritic and IL-17+ T cells. [PDF]

J Clin Invest
Huang X, Liu M, Gonzalez MV, Debnath R, Afzali H, Choi Y, Kim SA, Ko KI, Graves DT.   +8 more
europepmc   +1 more source

Elevated serum levels of IL-6 and IL-17 may associate with the development of ankylosing spondylitis.

, 2015
Wei Liu, WU Yuan-hao, Lei Zhang, Xiaoya Liu, Bin Xue, Yi Wang, Bin Liu, Qiao Jiang, Hou-Wen Kwang, Dong-Jing Wu   +9 more
openalex  

Some of the next articles are maybe not open access.

Related searches:

IL-17 for therapy

Journal of Dermatological Science, 2017
The cytokine IL-17 is now a target for an array of therapeutic monoclonal antibodies supposed to treat a variety of inflammatory diseases. The forerunner Secukinumab, an IL-17A neutralizing antibody, is meanwhile approved as first-line treatments for moderate-to-severe plaque psoriasis, and as second-line treatment for psoriatic arthritis and ...
Florian C, Kurschus, Sonja, Moos
openaire   +2 more sources